A patient with septic shock due to extensively-drug resistant (XDR) Pseudomonas aeruginosa 51 was cured by optimizing the meropenem (MEM) regimen to obtain at least 40% of the time 52 between two administrations in which drug levels were four times above the minimal 53 inhibitory concentration (MIC) of the pathogen. As standard drug dose did not achieve these 54 optimal concentrations, MEM regimen was progressively increased up to 12g/day (3g q6h in 55 3-hour extended infusion), which eventually resulted in sepsis resolution. High MEM dosage 56 may represent a valuable therapeutic option for infection due to MDR strains and drug 57 monitoring would allow rapid regimen adjustment in clinical practice. 58 59
Introduction. 75
Pseudomonas aeruginosa infections are associated with increased morbidity and mortality in 76 critically ill patients. Moreover, the increasing frequency of extensively-drug resistant (XDR) 77 strains of this pathogen is a considerable therapeutic challenge for clinicians (5, 11). Broad-78 spectrum β-lactams are the first therapeutic option for the treatment of P. aeruginosa 79 infections; however, in case of XDR strains, colistin or aminoglycosides remain the last 80 therapeutic option, but their effectiveness has been poorly demonstrated in this setting (6) . 81
The epidemic spread of XDR bacteria and the lack in the development of new drugs active 82 against these pathogens have forced clinicians to optimize the antimicrobial activity of the 83 available antibiotics (14). We report herein a case of septic shock due to P. aeruginosa that 84 was successfully treated by adapting the meropenem (MEM) regimen to the serum drug 85 concentrations and the in vitro pathogen susceptibility. 86
87

Case report. 88
A 70-year old obese man (body weight, BW = 120 kg; body mass index, BMI = 35) 89 was transferred to the Intensive Care Unit (ICU) from another hospital for a ventilator-90 associated pneumonia, developed few days after an elective tracheostomy. The patient had 91 prolonged mechanical ventilation (MV) after pulmonary oedema complicating an episode of 92 acute heart failure one month before and his tracheal aspirates were colonized by P. 93
aeruginosa. 94
At ICU admission, controlled volume MV was initiated and norepinephrine titrated to 95 achieve a mean arterial pressure of at least 70 mmHg; initial serum creatinine levels were 2.7 96 mg/dL and, because of concomitant oliguria, fluid resuscitation consisted of 5200 mL during 97 the first day of therapy. Blood cultures, as well as cultures from endotracheal aspirate, showed 98 P. aeruginosa, which was resistant to several antibiotics (including aztreonam, ceftazidime, The adequacy of MEM therapy was assessed by calculating the time that drug levels remained 109 above four times the MIC of the isolate (T > 4 x MIC) for an extensive period between two 110 doses; T > 4 x MIC was considered to be optimal if > 40% of the dose interval (13) . In both 111 measurements, drug concentrations were below this threshold (Table 1) . Because of persistent 112 septic shock, a broncho-alveolar lavage was performed at day 6 and yielded again P. do not need a so prolonged time of concentrations exceeding the MIC to be effective (13) . 155
Interestingly, MEM regimens resulted in a T>MIC of almost 100% for the different regimens 156 in our patient but clinical success was obtained only when drug concentrations exceeded 4 157 times the MIC for at least 40% of the dosing interval. 158
Human studies on serum concentrations of broad-spectrum β-lactams, such as 159 cephalosporins or piperacillin, have already reported that drug levels are insufficient in 160 patients with severe infections to treat less susceptible strains, while serum MEM 161 concentrations were found to be adequate in most of the critically ill patients with sepsis (17) . 162 Nevertheless, all of these studies considered only strains susceptible to the drug (MIC < 2 163 mg/L), while for less susceptible pathogens a higher than recommended regimen using 164 extended infusion would be necessary to optimize the efficacy of the drug (8). Importantly, as 165
shown in the present case, the low serum concentrations obtained with recommended doses 166 may have induced emergence of resistant strains and a favourable outcome can be obtained 167 only when serum concentrations reached levels corresponding to PK properties of β-lactams 168 (4). We did not measure colistin levels and cannot exclude any synergistic effect of 169 meropenem and colistin in the treatment of this XDR P. aeruginosa strain; however, patient 170 did not improve with this combination therapy and only the increase of meropenem regimen 171 to 12g/day allowed the resolution of the septic process. shown a better outcome using this strategy have come just from retrospective studies in 176 critically ill populations with pneumonia (9, 10). Second, when high doses are used to cure 177 less susceptible strains, over-dosing and toxicity of β-lactams could also be a concern so that 178 drug monitoring is mandatory in this setting to correctly adjust the dose (3). However, larger 179 than recommended carbapenem regimens have already been used in other diseases, such as 180 cystic fibrosis, to treat XDR pathogens, resulting in clinical success and being well tolerated 181 (2). Large prospective cohorts are needed to assess the influence on morbidity and mortality 182 of CI/EI administration, especially in patients with sepsis and infections caused by XDR 183
pathogens. 184 185
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